CEO Amir Heshmatpour buys 80,000 shares
CEO Amir Heshmatpour purchased 80,000 shares for $269,082 amid strong investment support and recent top-line clinical data, signaling long-term confidence in the CNS cancer biopharmaceutical.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed